Innovations in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing

Share this:
Published: 15 Mar 2019

The Life Science, Health & Wellness TechVision Opportunity Engine (TOE) details technology innovations across cell and gene therapies, regenerative medicine, synthetic biology, epitranscriptomics, CRISPR editing, biological computing, multiplexed assay and liquid biopsy platforms. It also comprises emerging developments across mass spectrometry, vaccines, protein therapies, transplantation techniques, small molecule, and organ-on-a-chip technologies. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cell therapy, gene therapy, small molecule therapy, protein therapy, epitranscriptomics, biological computing, synthetic biology, vaccines, 3D bioprinting, organ-on-a-chip, gene editing, CRISPR, multiplex assays, qPCR, liquid biopsy, regenerative medicine, transplantation, mass spectrometry, precision medicine



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..